Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study. I

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Pharma Global FZE

Criteria

Inclusion Criteria:

1. Provide written informed consent.

2. Male or female ≥ 18 years of age at time of screening

3. Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1 year) vitiligo

4. VASI of ≥ 4 at screening and baseline

Exclusion Criteria:

1. Segmental vitiligo, focal, or mixed Vitiligo

2. Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment

3. History of alcohol or drug abuse in the previous 2 years

4. Subjects who were submitted to melanocyte transfer

-